Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN.

Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to enhance early lung cancer detection.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Here is a look back on all the FDA happenings from the month of March 2025.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic graft-vs-host disease and reasons to select one over others.

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients with AML and MDS.

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

The impact of physical and nutritional rehabilitation post bone marrow transplant in patients with hematologic malignancies will be determined in the REBOOT trial.

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.

The combination of relacorilant and nab-paclitaxel improved progression-free and overall survival in patients with platinum-resistant ovarian cancer.

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint inhibitor–refractory patients with NSCLC.

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for extensive-stage small cell lung cancer.

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.